EcoDrugPlus

Tyrosinase

Ensembl ID : ENSACIG00000023289
Gene Symbol: TYR
1 Cross references
203 Possible Orthologues:

Tyrosinase

Ensembl ID : ENSACIG00000009762
Gene Symbol: TYR
2 Cross references
196 Possible Orthologues:

Tyrosine Hydroxylase

Ensembl ID : ENSACIG00000023618
Gene Symbol: TH
1 Cross references
188 Possible Orthologues:

Tyrosine Kinase 2

Ensembl ID : ENSACIG00000008801
Gene Symbol: TYK2
1 Cross references
196 Possible Orthologues:

V-Ki-Ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog

Ensembl ID : ENSACIG00000000100
Gene Symbol: KRAS
1 Cross references
208 Possible Orthologues:

V-Akt Murine Thymoma Viral Oncogene Homolog 2

Ensembl ID : ENSACIG00000020187
Gene Symbol: AKT2
1 Cross references
199 Possible Orthologues:

V-Akt Murine Thymoma Viral Oncogene Homolog 2, Like

Ensembl ID : ENSACIG00000021408
Gene Symbol: AKT2L
1 Cross references
176 Possible Orthologues:

V-Akt Murine Thymoma Viral Oncogene Homolog 2, Like

Ensembl ID : ENSACIG00000018062
Gene Symbol: AKT2L
1 Cross references
182 Possible Orthologues:

V-Akt Murine Thymoma Viral Oncogene Homolog 3a

Ensembl ID : ENSACIG00000008675
Gene Symbol: AKT3A
1 Cross references
203 Possible Orthologues:

V-Rel Avian Reticuloendotheliosis Viral Oncogene Homolog A

Ensembl ID : ENSACIG00000015978
Gene Symbol: RELA
1 Cross references
201 Possible Orthologues:

Vascular Endothelial Growth Factor Ab

Ensembl ID : ENSACIG00000017767
Gene Symbol: VEGFAB
1 Cross references
198 Possible Orthologues:

Vitamin D Receptor

Ensembl ID : ENSACIG00000016524
Gene Symbol: VDR
1 Cross references
392 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).